Listed medicines can only have low risk ingredients and can only make low level therapeutic indications (intended uses). People can self-select these medicines from shops and pharmacies.
In general, the risk of a medicine is based on its ingredients and/or its therapeutic indications (intended uses). Because listed medicines can only make low level indications (intended uses) and contain low risk ingredients they are lower risk than registered medicines or assessed listed medicines.
Listed medicines are sold in pharmacies and stores like health food shops and supermarkets. Listed medicines in the Australian Register of Therapeutic Goods (ARTG) are assigned an 'AUST L' identification number that must be displayed on the label.
Listed medicines are not individually evaluated by the TGA for quality, safety and efficacy before they are supplied in the marketplace. Instead, they are automatically included in the ARTG based on a certification by the sponsor (‘product owner’) that their medicine meets applicable legislative requirements in relation to safety, quality and efficacy. This allows for rapid market access compared with registered medicines. The TGA can undertake a compliance review of a listed medicine at any time.
Listed medicines must meet certain low risk criteria. For example they only contain:
- ingredients found in the Therapeutic Goods (Permissible Ingredients) Determination
- indications found in the Therapeutic Goods (Permissible Indications) Determination
The majority of listed medicines include complementary medicine ingredients e.g. vitamins, minerals and plant material. There are also non-complementary medicines (over-the-counter medicines) listed in the ARTG such as some sunscreens.
- Sanjin Watermelon Frost InsufflationProduct Defect Alert - Unclear instructions may result in overdose of boron
- Health supplements containing vitamin B6 can cause peripheral neuropathyBEWARE - Health supplements containing vitamin B6 can cause peripheral neuropathy
- GMP Clearance: Extension processing timesDelays in processing timeframes of applications to extend GMP Clearances.
- TGA publishes updated guidelines for sunscreensThe TGA has updated the Australian Regulatory Guidelines for Sunscreens (ARGS) to align with the data requirements for all ingredients proposed to be included in the Therapeutic Goods (Permissible Ingredients) Determination
- Update to listed medicine ingredients in May 2023Listed medicine ingredients and requirements for their use have been updated in the Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2023.
- Pharmacovigilance Inspection Program metrics report: Jan - Dec 2021The TGA Pharmacovigilance Inspection Program (PVIP) metrics report for 2021 is now available.
- Outcomes: Low-negligible risk changes to Permissible Ingredients - 2020-2021Outcomes following review of consultation submissions
- Pharmacovigilance Inspection Program metrics report: Jan - Dec 2020The PVIP aims to strengthen and broaden the TGA's post-market monitoring activities and protect public health